Actiq

Quick links to important sections

Actiq

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Actiq

Quick Facts

Property Description
Active ingredient Fentanyl (as fentanyl citrate)
Form Oral Transmucosal Lozenge (on a stick handle)
Pharmacological class Opioid Analgesic
General purpose Relief of abrupt, intense pain
Origin Synthetic

What Type of Medicine is Actiq and What is its Composition?

Actiq is a brand-name, prescription-only medication classified as a potent Opioid Analgesic, indicated for pain management in specific, opioid-tolerant patients. The active substance is Fentanyl (present as fentanyl citrate), which is a single-ingredient synthetic opioid compound. Fentanyl is recognized for its high potency. This compound is effective due to its powerful central nervous system action. Unlike other formulations of fentanyl, such as patches or injectables, Actiq is specifically designed as a lozenge to deliver the drug via a unique route.

What is Actiq’s Unique Dosage Form and Delivery Method?

The defining physical form of Actiq is an oral transmucosal lozenge attached to a plastic handle, categorized as a specialized solid dosage form. This medicine is designed specifically for transmucosal absorption, meaning the fentanyl is absorbed directly through the highly permeable lining of the mouth, rather than being swallowed. This method is a key differentiator from standard oral pills; it is associated with faster systemic absorption when compared to traditional gastrointestinal delivery. This rapid delivery is designed to quickly control periods of intense, abrupt pain.

What is the General Purpose of Actiq?

The general purpose of Actiq is to provide effective analgesia by modulating pain signals transmitted through the central nervous system. Its characteristic high potency and rapid-onset delivery system are intrinsically linked to its general therapeutic role, which is focused on the management of severe, sudden pain, such as an unexpected spike in discomfort that requires immediate action.

Regulatory References

  1. National Library of Medicine on Fentanyl
  2. Fentanyl's mechanism of action on the central nervous system (NIDA)

What side effects are possible with Actiq?

Possible Side Effects and Safety Information

The official safety profile for Actiq (fentanyl citrate) is structured around the risks inherent to potent opioid analgesics, as documented in regulatory sources like the FDA and EMA. The most significant safety concerns dictate strict usage requirements.


Serious and Life-Threatening Risks

Actiq is associated with the risk of life-threatening respiratory depression, particularly when administered to individuals who are not opioid tolerant, which is strictly contraindicated. The medication is classified as a Schedule II controlled substance due to the high risk of addiction, abuse, and misuse. Accidental ingestion of even a single dose, especially by children, can be fatal. Other serious documented risks include severe hypotension, Adrenal Insufficiency, and the potential for Serotonin Syndrome if used alongside other serotonergic drugs.


Common Adverse Reactions and Organ Systems

Commonly reported adverse reactions, based on regulatory frequency classifications (Very Common / Common), primarily affect the nervous and gastrointestinal systems:

System-Organ Class Most Common Adverse Reactions
Nervous System Somnolence (Drowsiness), Dizziness, Headache, Confusion
Gastrointestinal Nausea, Vomiting, Constipation
General Disorders Asthenia (Weakness)

Some adverse reactions, such as somnolence, may be observed more frequently during the initial titration phase of treatment. The peak respiratory depressive effects are typically noted within 15 to 30 minutes after administration begins.


Population-Specific Constraints

The medicine is strictly for use in patients already confirmed as opioid tolerant. Patients who are elderly, cachectic, or debilitated, as well as those with significant hepatic or renal impairment, must be observed carefully for signs of fentanyl toxicity, particularly during dose adjustments, as noted in the product labeling.

Overdose and Emergency Response

Overdose and when to seek help

The primary, life-threatening risk associated with an Actiq overdose is severe respiratory depression, which can be fatal. This outcome is especially dangerous if the product is used by an individual who is not opioid-tolerant, including children following accidental ingestion. Substitution of Actiq for any other fentanyl product can also lead to fatal overdose due to differing drug profiles.

Signs of a potential overdose involve pronounced central nervous system (CNS) and respiratory distress. These clinical manifestations include excessive drowsiness, slow or shallow breathing (hypoventilation), difficulty breathing, unusual snoring, cold and clammy skin, a slowed heartbeat, and the inability to wake up or respond. Chest or skeletal muscle rigidity may also occur.

Emergency Actions and When to Seek Help

If you suspect an overdose, or if a child or a non-opioid-tolerant adult has ingested Actiq, you must get emergency medical help right away or call 911. Immediate measures are required to secure a patent airway and provide assisted or controlled ventilation. If signs of excessive opioid effects appear before the lozenge is fully consumed, the unit must be immediately removed from the mouth and properly disposed of. Due to the high risk of life-threatening outcomes, specific regulatory guidance recommends that naloxone be considered for patients based on their individual overdose risk factors.

Therapeutic Uses of Actiq

Quick Facts

  • Condition Managed: Breakthrough pain in cancer patients.
  • Patient Profile: Used only in patients who are opioid tolerant.
  • Therapeutic Goal: To provide relief for episodic flares of pain.

Actiq (fentanyl citrate) is an established therapeutic option primarily indicated for the management of breakthrough pain in individuals diagnosed with cancer. Breakthrough pain refers to temporary, severe flares of pain that occur despite the patient already receiving around-the-clock opioid medication for their persistent underlying cancer pain.

This medication is strictly for use in patients considered opioid tolerant. Opioid tolerance is a requirement for treatment and must be established by a healthcare provider before use. It is not intended for the management of acute pain, such as post-operative discomfort, nor is it for use in patients who are not already on a continuous, chronic opioid regimen.

The medication is designed to address these sudden, episodic pain events.

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory documents define a highly restricted patient population for this medication. It is indicated only for managing breakthrough cancer pain in patients who are already receiving and are tolerant to an around-the-clock opioid regimen for their underlying persistent cancer pain.


Who May Use Actiq?

Criteria Requirement
Opioid Tolerance Status Patient must be opioid-tolerant, meaning they are taking stable, around-the-clock opioid therapy for at least one week.
Pain Type For cancer-related breakthrough pain only.
Age Patients must be 16 years of age or older.

Who Must Not Use Actiq? (Contraindications)

Actiq is contraindicated and must not be used in the following populations:

  • Opioid Non-Tolerant Patients: Use in non-tolerant individuals can result in fatal respiratory depression.
  • Acute Pain Management: Not for use in managing acute or postoperative pain, including dental pain or headache/migraine.
  • Respiratory Conditions: Patients with significant respiratory depression, acute or severe bronchial asthma, or severe obstructive lung conditions.
  • Gastrointestinal Conditions: Patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
  • Allergy: Individuals with a known hypersensitivity to fentanyl or any component of the formulation.

Use with Caution: Special consideration is required for patients with severe hepatic (liver) or renal (kidney) dysfunction, and those with chronic pulmonary disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail several critical interactions based on pharmacokinetic and pharmacodynamic effects.

Interacting Medicinal Product Categories

Interaction Domain Relevant Category Examples
Central Nervous System (CNS) Depressants Benzodiazepines, other opioids, sedatives, hypnotics, alcohol, tranquilizers
Cytochrome P450 3A4 (CYP3A4) Inhibitors Macrolide antibiotics (e.g., erythromycin), azole antifungal agents (e.g., ketoconazole), protease inhibitors
Cytochrome P450 3A4 (CYP3A4) Inducers Rifampin, carbamazepine, phenytoin, St. John's Wort
Serotonergic Drugs SSRIs, SNRIs, TCAs, Triptans, MAO Inhibitors
Mixed Agonist/Antagonist Opioids Pentazocine, nalbuphine, butorphanol, buprenorphine

Interaction-Related Requirements and Restrictions

The concomitant use of Actiq with CNS depressants increases the risk of severe respiratory depression, profound sedation, coma, and death. Regulatory labeling requires that co-prescribing be limited to patients for whom alternative options are inadequate, and both drug dosages should be limited to the minimum possible. The administration of Actiq with CYP3A4 inhibitors results in elevated fentanyl plasma concentrations, which may cause potentially fatal respiratory depression, and requires close monitoring. Conversely, discontinuing a CYP3A4 inducer can also lead to increased fentanyl concentrations. Use with MAO Inhibitors is strictly contraindicated, including within 14 days of taking the MAOI. The use of mixed agonist/antagonist or partial agonist opioids is to be avoided as it may reduce the analgesic effect of Actiq or precipitate opioid withdrawal symptoms.

Mechanism of Action

Actiq, which contains fentanyl citrate, exerts its biological action as a synthetic mu-opioid receptor (MOR) agonist. Fentanyl rapidly crosses the blood-brain barrier, targeting MORs located predominantly in the central nervous system, including the brain and spinal cord, as well as in peripheral tissues such as the gastrointestinal smooth muscle.

Upon binding, fentanyl induces a conformational change in the MOR, a G-protein coupled receptor (GPCR). This activation promotes the dissociation of the heterotrimeric G-protein subunits, specifically coupling the receptor to Gi/Go proteins. The resulting intracellular pathway involves the inhibition of adenylate cyclase, leading to a reduction in the synthesis of cyclic adenosine monophosphate (cAMP).

The decreased cAMP concentration modulates downstream effector systems. A critical consequence is the enhanced efflux of potassium ions (K^+) through G-protein-coupled inwardly rectifying potassium (GIRK) channels, resulting in cellular hyperpolarization. Simultaneously, the pathway suppresses voltage-gated calcium ion (Ca^2+) channel activity, reducing calcium influx.

These combined intracellular events decrease neuronal excitability and inhibit the release of pronociceptive neurotransmitters from afferent sensory neurons. At the system level, this modulation affects ascending and descending pathways in the central nervous system, resulting in altered signal transduction throughout the neuroaxis. Secondary systemic effects include increased vagal tone, leading to a decreased heart rate, and increased tone with decreased motility in the gastrointestinal tract.

Dosage and Administration Information

How Actiq is used: Official Administration Guidelines

Actiq (fentanyl citrate) is a highly potent analgesic used only in patients aged 16 and older who are opioid tolerant and receiving continuous opioid therapy for persistent pain.


Dosing and Titration Protocol

Dosing Step Instruction (Official Labeled Dose) Frequency and Limits
Initial Dose Always 200 µg (micrograms) for the first breakthrough pain episode. Initial titration supply limited to six 200 µg units.
Titration Individually adjust the dose upwards from 200 µg to the next available strength until a successful dose is found (relief with a single unit). Dose is increased only when the current dose fails for several consecutive episodes.
Maintenance Limit Once the successful dose (200 µg to 1600 µg) is established, limit consumption to four or fewer units per day.

Administration Method and Timing

Actiq is designed for Oromucosal/Oral Transmucosal administration, meaning absorption through the lining of the mouth, not the stomach. The lozenge must be removed from its protective blister and administered as follows:

  1. Place the unit between the cheek and lower gum and suck it gently; do not chew.
  2. Consume the unit over a 15-minute period.
  3. If the pain is not relieved 15 minutes after the first unit is completed, a maximum of one additional unit of the same successful strength may be taken for that single pain episode.
  4. Patients must wait at least 4 hours before treating another, separate episode of pain.

Special Conditions: The lozenge may be used before or after, but not during, meals. Patients over 65 years of age may require a lower dose for effective relief.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Actiq (Fentanyl Citrate)

This overview describes the official research landscape for Actiq, detailing the types of studies conducted and what outcomes they observed, without providing medical advice or recommendations.


Evidence for Use in Breakthrough Cancer Pain

Actiq was studied in research exploring its approved use for breakthrough pain in patients with cancer who are already receiving continuous, around-the-clock opioid medication. Research primarily consists of multiple randomized controlled trials (RCTs) that often employed a double-blind, placebo-controlled, crossover design, which is commonly used in research exploring short-term effects.

The research examined outcomes related to patient-reported discomfort, specifically the rapid change in the intensity of acute, sudden symptoms. Studies monitored patient-reported outcomes describing perceived discomfort over very brief, defined time intervals, usually measured in minutes. Findings describe patterns observed in the studies related to how pain measurements evolved after administering the study medication compared to a placebo. Studies contribute to the broader evidence landscape by characterizing the delivery profile in these conditions involving periods of heightened symptoms.


Comparative Studies and Measurements of Effect

Research examined how Actiq was evaluated against both a placebo and, in some cases, immediate-release oral opioids like morphine sulfate. These studies were observed in research exploring short-term symptom changes that were relevant in trials assessing short-term or episodic symptom patterns. The specific measurements used in research exploring how symptoms change over time included formalized pain intensity difference (PID) scales and patient ratings of the overall performance of the medication for the episode.

A study comparing the lozenge to immediate-release oral morphine reported differences related to the measurement of change in symptom intensity over short time intervals. However, the evidence is limited in terms of direct, head-to-head comparisons against all other modern immediate-release fentanyl formulations currently available on the market.


What Is Still Uncertain About Actiq

Research highlights what is known—and what is still uncertain—about this medication. One key limitation is the narrow population scope: the evidence is highly specific to cancer-related breakthrough pain in opioid-tolerant individuals. Comparative evidence is lacking for its use in patients with non-cancer pain or acute pain.

Additionally, the required dose may vary significantly among patients, and the individualized dose was not consistently related to a patient's existing long-acting opioid dose. This individual variability was observed to be a key factor in the dosing process for the studies. Final evaluation was observed in some studies against placebo, but comparative evidence is lacking for a direct, microgram-per-microgram comparison with all other specialized immediate-release fentanyl products.

Key Studies & References

  1. National Comprehensive Cancer Network (NCCN) Guidelines: Adult Cancer Pain (Used for context on breakthrough pain definition/guidance)

Frequently Asked Questions (FAQ)

Common questions about Actiq (FAQ)


Q: Is Actiq the same as morphine or oxycodone?

Official information indicates that Actiq contains fentanyl, which is classified as a synthetic opioid. While it belongs to the same general class of medicines as morphine and oxycodone, it is chemically distinct. Actiq is also specifically designated by regulatory agencies as a Schedule II controlled substance.


Q: Can Actiq interact with common cold or allergy medicines?

Official labeling states that Actiq can interact with certain cold and allergy medicines. Products that act as CNS depressants (causing sedation) or serotonergic drugs carry an increased risk of severe adverse effects, such as excessive sedation or Serotonin Syndrome. Regulatory documents require that co-prescribing with such products be limited to the minimum necessary dose.


Q: What are some signs that Actiq may be interacting with another medication?

Official warnings describe signs of a serious interaction, particularly when Actiq is taken with other sedating medicines. These signs can include unusual dizziness, extreme sleepiness, slowed or difficult breathing, or becoming unresponsive. Official information emphasizes the need to contact a healthcare provider immediately if these symptoms occur.


Q: Do people typically experience withdrawal symptoms if Actiq is stopped?

Regulatory warnings state that the prolonged use of fentanyl can result in the development of physical dependence. If treatment is stopped suddenly, patients may experience withdrawal symptoms. In some cases, healthcare providers may use gradually reducing the dose as a strategy to manage withdrawal symptoms.


Q: What are the main active and inactive ingredients in Actiq?

The active ingredient in Actiq is fentanyl, in the form of fentanyl citrate. Inactive ingredients listed in the product description include hydrated dextrates (sugar), citric acid, dibasic sodium phosphate, artificial berry flavor, magnesium stearate, modified food starch, and confectioner’s sugar.


Q: What is the difference between chronic pain and breakthrough pain, in the context of Actiq?

Regulatory documents state that Actiq is only indicated for breakthrough pain, which is defined as a temporary spike in pain intensity. This is distinct from the underlying persistent (chronic) pain, for which patients are already required to be taking continuous, around-the-clock opioid medication.


Q: Why is Actiq only used for 'breakthrough pain'?

Actiq is specifically designed for rapid absorption through the mouth, which is intended for use in treating sudden, intense pain flares. Regulatory documents emphasize that it is contraindicated (must not be used) for general acute or postoperative pain management due to the high risk of life-threatening respiratory depression in patients who are not opioid tolerant.


Q: Does Actiq contain lactose?

According to the official list of ingredients in the product description, Actiq does not contain lactose. However, it does contain other forms of sugar, including hydrated dextrates and confectioner's sugar.


Q: Why is Actiq packaged with a special stick or handle?

The stick acts as an integral applicator that helps position the lozenge inside the mouth for proper absorption. Regulatory documents also note that the handle allows the unit to be removed immediately if signs of excessive opioid effects (like dizziness or sickness) appear during administration.


Q: What happens if I accidentally swallow the medicine too quickly?

The official administration instructions require the lozenge to be consumed over 15 minutes to allow absorption through the lining of the mouth. If the medicine is swallowed quickly, more of the drug will be absorbed through the stomach, which may result in less effective pain relief for the specific pain episode.


Q: Does grapefruit juice affect Actiq?

Official drug interaction warnings state that grapefruit juice can increase the level of fentanyl in the body. Because fentanyl is highly potent, this interaction can significantly raise the risk of serious adverse effects. Regulatory labeling recommends avoiding the consumption of grapefruit juice.


Q: Is Actiq part of a Risk Evaluation and Mitigation Strategy (REMS) program?

Yes, regulatory documents confirm that Actiq is available only through a restricted program mandated by the FDA called a Risk Evaluation and Mitigation Strategy (REMS). This program is specifically known as the Transmucosal Immediate Release Fentanyl (TIRF) REMS Access program.


Q: What is the purpose of the 'Risk Management Plan' associated with Actiq?

The purpose of the Risk Management Plan, as outlined in regulatory documentation, is to mitigate the risks associated with the use of transmucosal immediate-release fentanyl medicines. These risks include the potential for misuse, abuse, addiction, overdose, and serious complications due to medication errors.


Q: What does official guidance say about driving or operating machinery while using Actiq?

Official warnings state that fentanyl can cause side effects like dizziness, somnolence (drowsiness), and clouding of consciousness. Official guidance states that patients must avoid driving or operating heavy machinery until the effects of the drug are known and they are safely capable of performing these tasks.


Q: Can Actiq be used during pregnancy or while breastfeeding?

Regulatory information indicates that prolonged use during pregnancy can lead to Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn. Regarding breastfeeding, regulatory information documents that the manufacturer does not recommend it for a specific period (e.g., 48 hours) after the last dose.


Q: Is there a link between Actiq and dental issues?

Yes, official safety information highlights a link between Actiq and dental issues. Since the lozenge contains sugar, its frequent use increases the risk of dental decay (caries). The risk is potentially heightened because fentanyl can cause dry mouth, which can affect dental health. The official safety documentation includes a recommendation for regular dental visits.


Q: Can Actiq cause dry mouth?

Yes, dry mouth is listed in regulatory documents as a common adverse effect associated with the use of fentanyl. This is a recognized side effect for this class of medicine.


Q: Are there any specific side effects related to long-term use of Actiq?

Studies and official information indicate that long-term use of Actiq, like other opioids, can lead to physical dependence. In some rare instances, long-term opioid use has been associated with a phenomenon called hyperalgesia, which involves an increased sensitivity to pain.


Q: What should a person do if they notice unusual side effects after using Actiq?

The official patient guidance stresses the need to contact a healthcare provider immediately if severe or concerning symptoms are experienced. This includes signs such as slowed breathing, extreme drowsiness, dizziness, or any other new symptoms that cause concern.

How should Actiq be stored and disposed of?

Actiq Storage and Disposal Instructions

Actiq (fentanyl citrate) must be stored and disposed of according to strict regulations to prevent fatal overdose from accidental ingestion, especially by children, and to deter misuse.

Storage and Security

Storage Requirements

Condition Official Requirement
Temperature Store at controlled room temperature (59 F to 86 F or 15 C to 30 C). Do not freeze.
Container Keep in the original sealed child-resistant blister package until use.
Child Safety Must be stored securely, out of sight and reach of children, and protected from theft.

Disposal Requirements

Disposal of Units

Unit Type Official Disposal Instruction
Used Units Place under hot running water until all medicine is completely gone before discarding the handle.
Unused/Unwanted Units Flush down the toilet immediately when drug take-back options are unavailable, as recommended by the FDA to remove the immediate hazard.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Actiq found in:

A-Z Index: